More than 20 years back, lung cancer patients did not have many treatment options and most patients died very quickly.

Now there is an explosion of choices for patients with a type called “non-small cell lung cancer”.

Lot of new drugs were presented and discussed at the ASCO 2026 Annual Meeting in Chicago ( ASCO- American Society of Clinical Oncology).

Sunvozertinib: Abstract LBA8500

Amivantamab plus lazertinib in atypical EGFR-mutated NSCLC: Abstract 8501

Neladalkib in patients with advanced ALK+ NSCLC: Abstract 8503

Pralsetinib as first-line treatment of RET fusion–positive: Abstract 8504

Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab: Abstract 8506

Benmelstobart plus chemotherapy and Anlotinib: Abstract LBA8507

The subset of patients cancers, who can be targeted by therapy would have prognosis improved by these drugs.

I am not publishing this blog as a lung cancer expert recommending treatments. Please DO consult your own doctor to discuss concerns and treatment options, which are directly relevant and specific to you.

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information research only and do check the sources where cited. But the author cannot vouch for scientific integrity of the sources cited and author is not responsible for any information in any advert on those cited pages. Please DO consult your own doctor to discuss concerns and options, which are directly relevant and specific to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting this blog and MAY CHANGE overtime, particularly when new evidence comes to light.